Banking & Finance  August 19, 2019

BioPlx raises $1.64M in first funding round

By

BOULDER  — BioPlx Inc., a company producing treatments to prevent recurring staph infections, has closed on a $1,641,415 fundraising round Monday morning.

The Boulder-based biotreatment company raised the funds from 12 investors in an all-equity offering after opening the round in mid-June, according to filings with the U.S. Securities and Exchange Commission.

It was the company’s first fundraising round recorded with the SEC.

BioPlx’s main focus is developing non-antibiotic treatments for strains of MRSA, a type of staph infection that is increasingly resistant to traditional antibiotics. The U.S. Centers for Disease Control estimates that at least two million people per year contract…

Christopher Wood
Christopher Wood is editor and publisher of BizWest, a regional business journal covering Boulder, Broomfield, Larimer and Weld counties. Wood co-founded the Northern Colorado Business Report in 1995 and served as publisher of the Boulder County Business Report until the two publications were merged to form BizWest in 2014. From 1990 to 1995, Wood served as reporter and managing editor of the Denver Business Journal. He is a Marine Corps veteran and a graduate of the University of Colorado Boulder. He has won numerous awards from the Colorado Press Association, Society of Professional Journalists and the Alliance of Area Business Publishers.
Categories: Banking & Finance Boulder Morning Edition Technology Today's News

Related Posts

Sign up for BizWest Daily Alerts